P3 Health Partners (PIII) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Voting matters and shareholder proposals
Election of three Class II directors to serve until the 2029 Annual Meeting, with nominees Amir Bacchus, M.D., Mark Thierer, and Lawrence B. Leisure recommended for election.
Ratification of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Advisory approval of executive compensation for named executive officers.
Approval of the issuance of up to 3,341,130 shares of Class A common stock upon exercise of outstanding warrants held by VBC Growth SPV 5, LLC, in accordance with Nasdaq Listing Rule 5635(d).
Consideration of any other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends all director nominees for election to serve until 2029, ensuring continuity in governance.
Executive compensation and say-on-pay
Shareholders are asked to approve, on a non-binding advisory basis, the compensation of named executive officers.
Latest events from P3 Health Partners
- Raised 2026 guidance to $1.5B–$1.6B revenue and $80M–$110M adjusted EBITDA, driven by value-based care.PIII
Investor presentation - Q2 2026 delivered strong profitability, raised guidance, but ongoing liquidity risks persist.PIII
Q2 2026 - All four shareholder proposals were approved, with no questions raised by stockholders.PIII
AGM 2026 - Q1 2026 delivered $3M net income and $26M adjusted EBITDA, but liquidity risks remain.PIII
Q1 2026 - 2026 guidance targets $1.5B–$1.65B revenue and $20M–$60M adjusted EBITDA amid strategic growth.PIII
Investor presentation - Revenue up 26% but net loss widened to $102.9M; liquidity risks remain.PIII
Q3 2024 - Q2 revenue up 15% to $379M, but profitability declined and liquidity risks persist.PIII
Q2 2024 - Q1 2025 saw revenue and membership decline, improved MLR, and ongoing liquidity risks.PIII
Q1 2025 - 2025 guidance reaffirmed with profitability expected, despite a deeper 2024 net loss.PIII
Q4 2024